BYND vs. MRNA
BYND (Beyond Meat, Inc.) and MRNA (Moderna, Inc.) are both stocks. BYND operates in Packaged Foods (Consumer Defensive), while MRNA operates in Biotechnology (Healthcare). Over the past 5 years, BYND returned -65.98%/yr vs -25.59%/yr for MRNA. At a 0.25 correlation, their price movements are largely independent.
Performance
BYND vs. MRNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BYND achieves a -16.91% return, which is significantly lower than MRNA's 69.24% return.
BYND
- 1D
- -3.20%
- 1M
- -15.29%
- YTD
- -16.91%
- 6M
- -37.50%
- 1Y
- -78.44%
- 3Y*
- -63.44%
- 5Y*
- -65.98%
- 10Y*
- —
MRNA
- 1D
- 0.54%
- 1M
- 1.77%
- YTD
- 69.24%
- 6M
- 69.42%
- 1Y
- 87.14%
- 3Y*
- -26.94%
- 5Y*
- -25.59%
- 10Y*
- —
BYND vs. MRNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BYND Beyond Meat, Inc. | -16.91% | -78.19% | -57.75% | -27.70% | -81.11% | -47.87% | 65.34% | 64.35% |
MRNA Moderna, Inc. | 69.24% | -29.08% | -58.19% | -44.63% | -29.28% | 143.11% | 434.10% | -25.91% |
Correlation
The correlation between BYND and MRNA is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.30 |
Correlation (All Time) Calculated using the full available price history since May 2, 2019 | 0.25 |
Fundamentals
BYND:
$325.51M
MRNA:
$19.71B
BYND:
$1.03
MRNA:
-$8.16
BYND:
0.52
MRNA:
8.78
BYND:
4.35
MRNA:
2.66
BYND:
$275.50M
MRNA:
$2.23B
BYND:
$7.65M
MRNA:
-$309.00M
BYND:
-$290.85M
MRNA:
-$3.02B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BYND vs. MRNA — Risk / Return Rank
BYND
MRNA
BYND vs. MRNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Beyond Meat, Inc. (BYND) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BYND | MRNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.62 | ||
| Sortino ratioReturn per unit of downside risk | -1.71 | ||
| Omega ratioGain probability vs. loss probability | 1.05 | 1.24 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | -0.90 | 2.34 | -3.24 |
| Martin ratioReturn relative to average drawdown | -1.19 | 4.59 | -5.77 |
Loading charts...
Drawdowns
BYND vs. MRNA - Drawdown Comparison
The maximum BYND drawdown since its inception was -99.78%, roughly equal to the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for BYND and MRNA.
Loading charts...
Drawdown Indicators
| BYND | MRNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.78% | -95.38% | -4.40% |
Max Drawdown (1Y)Largest decline over 1 year | -87.85% | -35.51% | -52.34% |
Max Drawdown (3Y)Largest decline over 3 years | -97.06% | -86.58% | -10.48% |
Max Drawdown (5Y)Largest decline over 5 years | -99.67% | -95.38% | -4.29% |
Current DrawdownCurrent decline from peak | -99.71% | -89.70% | -10.01% |
Average DrawdownAverage peak-to-trough decline | -75.62% | -57.06% | -18.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 66.55% | 18.06% | +48.49% |
Volatility
BYND vs. MRNA - Volatility Comparison
Beyond Meat, Inc. (BYND) has a higher volatility of 20.19% compared to Moderna, Inc. (MRNA) at 17.56%. This indicates that BYND's price experiences larger fluctuations and is considered to be riskier than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BYND | MRNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.19% | 17.56% | +2.63% |
Volatility (6M)Calculated over the trailing 6-month period | 75.70% | 48.82% | +26.88% |
Volatility (1Y)Calculated over the trailing 1-year period | 236.92% | 64.75% | +172.17% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 126.82% | 66.49% | +60.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 117.26% | 72.15% | +45.11% |
Dividends
BYND vs. MRNA - Dividend Comparison
Neither BYND nor MRNA has paid dividends to shareholders.
Financials
BYND vs. MRNA - Financials Comparison
This section allows you to compare key financial metrics between Beyond Meat, Inc. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BYND and MRNA have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BYND has higher volatility (20.19%) compared to MRNA (17.56%). In terms of maximum drawdown, BYND dropped -99.78% vs MRNA's -95.38%.
MRNA currently has the higher Sharpe Ratio (1.28 vs -0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BYND and MRNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer